Leadership and Operations Center (LOC): Microbicide Trials Network View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2006-2021

FUNDING AMOUNT

178287648.0 USD

ABSTRACT

DESCRIPTION: Component 1 (Overview): The MTN Leadership Group comprises a Leadership Operations Center (LOC), Laboratory Center (LC), and Statistical and Data Management Center (SDMC), for each of which thematically linked but separate applications have been submitted. The LOC is led by two Principal Investigators: Drs. Sharon Hillier and Ian McGowan, both located at the Magee Womens Research Institute in Pittsburgh, each providing distinct but complementary expertise. Dr. Hillier provides primary leadership for MTN's vaginal microbicide development and female reproductive health; Dr. McGowan leads the MTN rectal microbicide research agenda and mucosal immunology program. The LOC also comprises the PIs for the Operations Support Core (Cates), University of Washington Core (Celum), the LC (Dezzutti), and the SDMC (Brown), which work together and with the network-affiliated Clinical Trial Units/Sites to implement the research agenda. The LOC is supported by 3 Working Groups--Biomedical Science, Behavioral Research, and Community--and 3 Network Committees: Study Monitoring, Network Evaluation, and Manuscript Development. The PIs and the Chairs of the Working Groups and Network Committees constitute the MTN Executive Committee, the primary decision-making body for MTN activity. Established in 2006 with NIH funding, the MTN was charged with developing safe and effective microbicides from the early stages of product development through final approval by regulatory authorities. The present grant application details MTN contributions to HIV prevention, defines network leadership and operational structures for the next funding cycle--a 7-year period from 12/1/13 through 11/30/20-and describes 6 specific areas of challenge and needed improvement. The application presents 15 Specific Aims for MTN that build on its 6 years of experience with developing and/or completing 33 clinical protocols, associated lessons learned, obstacles encountered, gaps identified; and environmental changes and pressures. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=10174309

Related SciGraph Publications

  • 2021-11-02. Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial in AIDS AND BEHAVIOR
  • 2021-10-17. Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026) in AIDS AND BEHAVIOR
  • 2021-09-23. Ethical considerations for involving adolescents in biomedical HIV prevention research in BMC MEDICAL ETHICS
  • 2021-08-14. Inconsistent Counselor Fidelity in Delivering an Evidence-Based Adherence Intervention During a PrEP Trial in AIDS AND BEHAVIOR
  • 2021-06-28. Using Emoji Stickers to Understand End-User Opinions of the Dapivirine Vaginal Ring for HIV Prevention in AIDS AND BEHAVIOR
  • 2021-06-11. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention in AIDS AND BEHAVIOR
  • 2021-05-19. Impact of Women’s Home Environment on Use of the Dapivirine Vaginal Ring for HIV Prevention in Sub-Saharan Africa in AIDS AND BEHAVIOR
  • 2021-05-03. The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence in AIDS AND BEHAVIOR
  • 2021-04-23. Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa in BMC WOMEN'S HEALTH
  • 2021-03-25. Acceptability and feasibility of the CHARISMA counseling intervention to support women’s use of pre-exposure prophylaxis: results of a pilot study in BMC WOMEN'S HEALTH
  • 2021-03-13. Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial in AIDS AND BEHAVIOR
  • 2021-01-02. Men’s Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and Zimbabwe in AIDS AND BEHAVIOR
  • 2020-09-12. Sharing Objective Measures of Adherence to a Vaginal Microbicide Promotes Candor About Actual Use and Bolsters Motivation to Prevent HIV in AIDS AND BEHAVIOR
  • 2020-08-24. Client-Centered Adherence Counseling with Adherence Measurement Feedback to Support Use of the Dapivirine Ring in MTN-025 (The HOPE Study) in AIDS AND BEHAVIOR
  • 2020-01-24. The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants’ Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention in AIDS AND BEHAVIOR
  • 2019-10-30. Impact of Male Partner Involvement on Women’s Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial in AIDS AND BEHAVIOR
  • 2019-05-20. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial in AIDS AND BEHAVIOR
  • 2019-04-27. Hygiene, Blood Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring During Menstruation in Malawi, South Africa, Uganda and Zimbabwe in AIDS AND BEHAVIOR
  • 2019-03-15. A Mixed-Methods Study Examining Adherence to and Acceptability of Intravaginal Rings for HIV Prevention: Behavioral Results of MTN-027 in AIDS AND BEHAVIOR
  • 2019-01-25. Understanding women’s motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence in BMC WOMEN'S HEALTH
  • 2019-01-21. Debrief Reports to Expedite the Impact of Qualitative Research: Do They Accurately Capture Data from In-depth Interviews? in AIDS AND BEHAVIOR
  • 2018-09-14. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE in AIDS AND BEHAVIOR
  • 2017-11-18. Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex in AIDS AND BEHAVIOR
  • 2017-11-08. Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men in AIDS AND BEHAVIOR
  • 2017-10-26. Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017 in AIDS AND BEHAVIOR
  • 2017-09-27. Prevalent Herpes Simplex Virus-2 Increases the Risk of Incident Bacterial Vaginosis in Women from South Africa in AIDS AND BEHAVIOR
  • 2017-08-19. Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial in AIDS AND BEHAVIOR
  • 2017-05-26. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States in AIDS AND BEHAVIOR
  • 2017-01-21. How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe in AIDS AND BEHAVIOR
  • 2016-11-17. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants’ Explanations for Dishonesty in AIDS AND BEHAVIOR
  • 2016-05-04. Sharing of Investigational Drug Among Participants in the Voice Trial in AIDS AND BEHAVIOR
  • 2016-02-23. Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit? in AIDS AND BEHAVIOR
  • 2016-02-02. Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States in AIDS AND BEHAVIOR
  • 2015-07-01. Condoms, Lubricants and Rectal Cleansing: Practices Associated with Heterosexual Penile-Anal Intercourse Amongst Participants in an HIV Prevention Trial in South Africa, Uganda and Zimbabwe in AIDS AND BEHAVIOR
  • 2015-06-16. Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention in PHARMACEUTICAL RESEARCH
  • 2015-05-13. Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions in AIDS AND BEHAVIOR
  • 2015-05-01. Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa in AIDS AND BEHAVIOR
  • 2015-02-14. Factors associated with bone mineral density in healthy African women in ARCHIVES OF OSTEOPOROSIS
  • 2014-11-22. Male Partner Influence on Women’s HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of “Understanding” in AIDS AND BEHAVIOR
  • 2014-11-11. Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial in AIDS AND BEHAVIOR
  • 2014-07-28. Influences on visit retention in clinical trials: Insights from qualitative research during the VOICE trial in Johannesburg, South Africa in BMC WOMEN'S HEALTH
  • 2013-10-26. Effects of Partnership Change on Microbicide Gel Adherence in a Clinical Trial (HPTN 035) in AIDS AND BEHAVIOR
  • 2013-07-11. Use of a Novel Technology to Track Adherence to Product Use in a Microbicide Trial of Short Duration (MTN-007) in AIDS AND BEHAVIOR
  • 2013-02-23. Adherence Support Approaches in Biomedical HIV Prevention Trials: Experiences, Insights and Future Directions from Four Multisite Prevention Trials in AIDS AND BEHAVIOR
  • 2012-12-09. Use of Human Mucosal Tissue to Study HIV-1 Pathogenesis and Evaluate HIV-1 Prevention Modalities in CURRENT HIV/AIDS REPORTS
  • 2012-10-07. Feasibility, Performance, and Acceptability of the Wisebag™ for Potential Monitoring of Daily Gel Applicator Use in Durban, South Africa in AIDS AND BEHAVIOR
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "amount": {
          "currency": "USD", 
          "type": "MonetaryAmount", 
          "value": 178287648.0
        }, 
        "description": "DESCRIPTION: Component 1 (Overview): The MTN Leadership Group comprises a Leadership Operations Center (LOC), Laboratory Center (LC), and Statistical and Data Management Center (SDMC), for each of which thematically linked but separate applications have been submitted. The LOC is led by two Principal Investigators: Drs. Sharon Hillier and Ian McGowan, both located at the Magee Womens Research Institute in Pittsburgh, each providing distinct but complementary expertise. Dr. Hillier provides primary leadership for MTN's vaginal microbicide development and female reproductive health; Dr. McGowan leads the MTN rectal microbicide research agenda and mucosal immunology program. The LOC also comprises the PIs for the Operations Support Core (Cates), University of Washington Core (Celum), the LC (Dezzutti), and the SDMC (Brown), which work together and with the network-affiliated Clinical Trial Units/Sites to implement the research agenda. The LOC is supported by 3 Working Groups--Biomedical Science, Behavioral Research, and Community--and 3 Network Committees: Study Monitoring, Network Evaluation, and Manuscript Development. The PIs and the Chairs of the Working Groups and Network Committees constitute the MTN Executive Committee, the primary decision-making body for MTN activity. Established in 2006 with NIH funding, the MTN was charged with developing safe and effective microbicides from the early stages of product development through final approval by regulatory authorities. The present grant application details MTN contributions to HIV prevention, defines network leadership and operational structures for the next funding cycle--a 7-year period from 12/1/13 through 11/30/20-and describes 6 specific areas of challenge and needed improvement. The application presents 15 Specific Aims for MTN that build on its 6 years of experience with developing and/or completing 33 clinical protocols, associated lessons learned, obstacles encountered, gaps identified; and environmental changes and pressures.", 
        "endDate": "2021-11-30", 
        "funder": {
          "id": "http://www.grid.ac/institutes/grid.419681.3", 
          "type": "Organization"
        }, 
        "id": "sg:grant.2705268", 
        "identifier": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "grant.2705268"
            ]
          }, 
          {
            "name": "nih_id", 
            "type": "PropertyValue", 
            "value": [
              "UM1AI068633"
            ]
          }
        ], 
        "inLanguage": [
          "en"
        ], 
        "keywords": [
          "Laboratory Center", 
          "female reproductive health", 
          "Microbicide Trials Network", 
          "HIV prevention", 
          "effective microbicide", 
          "microbicide development", 
          "reproductive health", 
          "clinical protocols", 
          "Trials Network", 
          "Working Group", 
          "NIH funding", 
          "years of experience", 
          "principal investigator", 
          "specific aim", 
          "group", 
          "final approval", 
          "early stages", 
          "microbicides", 
          "manuscript development", 
          "center", 
          "funding cycle", 
          "Committee", 
          "prevention", 
          "health", 
          "regulatory authorities", 
          "approval", 
          "investigators", 
          "management center", 
          "aim", 
          "years", 
          "DR", 
          "development", 
          "complementary expertise", 
          "component 1", 
          "Executive Committee", 
          "Pittsburgh", 
          "behavioral research", 
          "period", 
          "leadership group", 
          "PI", 
          "activity", 
          "evaluation", 
          "specific areas", 
          "Institute", 
          "protocol", 
          "research agenda", 
          "improvement", 
          "experience", 
          "pressure", 
          "changes", 
          "body", 
          "monitoring", 
          "chair", 
          "stage", 
          "program", 
          "Data Management Center", 
          "sites", 
          "funding", 
          "Research Institute", 
          "expertise", 
          "network committees", 
          "area", 
          "separate application", 
          "challenges", 
          "cycle", 
          "McGowan", 
          "SDMC", 
          "University", 
          "biomedical sciences", 
          "research", 
          "MTN", 
          "community", 
          "lessons", 
          "obstacles", 
          "Operations Center", 
          "contribution", 
          "support cores", 
          "gap", 
          "leadership", 
          "authorities", 
          "agenda", 
          "science", 
          "applications", 
          "decision-making bodies", 
          "Hillier", 
          "network leadership", 
          "core", 
          "operational structure", 
          "network evaluation", 
          "network", 
          "structure", 
          "product development", 
          "environmental changes", 
          "Statistical", 
          "primary leadership"
        ], 
        "name": "Leadership and Operations Center (LOC): Microbicide Trials Network", 
        "recipient": [
          {
            "id": "http://www.grid.ac/institutes/grid.460217.6", 
            "type": "Organization"
          }, 
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/None", 
              "name": "MAGEE-WOMEN'S RES INST AND FOUNDATION", 
              "type": "Organization"
            }, 
            "familyName": "HILLIER", 
            "givenName": "SHARON L.", 
            "id": "sg:person.01036244723.95", 
            "type": "Person"
          }, 
          {
            "member": "sg:person.01036244723.95", 
            "roleName": "PI", 
            "type": "Role"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/details/grant/grant.2705268"
        ], 
        "sdDataset": "grants", 
        "sdDatePublished": "2021-12-01T20:14", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/grant/grant_19.jsonl", 
        "startDate": "2006-06-29", 
        "type": "MonetaryGrant", 
        "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=10174309"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2705268'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2705268'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2705268'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2705268'


     

    This table displays all metadata directly associated to this object as RDF triples.

    140 TRIPLES      19 PREDICATES      117 URIs      109 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:grant.2705268 schema:about anzsrc-for:11
    2 schema:amount N9d6b0ecc05304eb58b7fb98e707f469e
    3 schema:description DESCRIPTION: Component 1 (Overview): The MTN Leadership Group comprises a Leadership Operations Center (LOC), Laboratory Center (LC), and Statistical and Data Management Center (SDMC), for each of which thematically linked but separate applications have been submitted. The LOC is led by two Principal Investigators: Drs. Sharon Hillier and Ian McGowan, both located at the Magee Womens Research Institute in Pittsburgh, each providing distinct but complementary expertise. Dr. Hillier provides primary leadership for MTN's vaginal microbicide development and female reproductive health; Dr. McGowan leads the MTN rectal microbicide research agenda and mucosal immunology program. The LOC also comprises the PIs for the Operations Support Core (Cates), University of Washington Core (Celum), the LC (Dezzutti), and the SDMC (Brown), which work together and with the network-affiliated Clinical Trial Units/Sites to implement the research agenda. The LOC is supported by 3 Working Groups--Biomedical Science, Behavioral Research, and Community--and 3 Network Committees: Study Monitoring, Network Evaluation, and Manuscript Development. The PIs and the Chairs of the Working Groups and Network Committees constitute the MTN Executive Committee, the primary decision-making body for MTN activity. Established in 2006 with NIH funding, the MTN was charged with developing safe and effective microbicides from the early stages of product development through final approval by regulatory authorities. The present grant application details MTN contributions to HIV prevention, defines network leadership and operational structures for the next funding cycle--a 7-year period from 12/1/13 through 11/30/20-and describes 6 specific areas of challenge and needed improvement. The application presents 15 Specific Aims for MTN that build on its 6 years of experience with developing and/or completing 33 clinical protocols, associated lessons learned, obstacles encountered, gaps identified; and environmental changes and pressures.
    4 schema:endDate 2021-11-30
    5 schema:funder grid-institutes:grid.419681.3
    6 schema:identifier N18cace79fde049d8aa974f21707a9086
    7 Ncd09402082b440a3946696a4a2899100
    8 schema:inLanguage en
    9 schema:keywords Committee
    10 DR
    11 Data Management Center
    12 Executive Committee
    13 HIV prevention
    14 Hillier
    15 Institute
    16 Laboratory Center
    17 MTN
    18 McGowan
    19 Microbicide Trials Network
    20 NIH funding
    21 Operations Center
    22 PI
    23 Pittsburgh
    24 Research Institute
    25 SDMC
    26 Statistical
    27 Trials Network
    28 University
    29 Working Group
    30 activity
    31 agenda
    32 aim
    33 applications
    34 approval
    35 area
    36 authorities
    37 behavioral research
    38 biomedical sciences
    39 body
    40 center
    41 chair
    42 challenges
    43 changes
    44 clinical protocols
    45 community
    46 complementary expertise
    47 component 1
    48 contribution
    49 core
    50 cycle
    51 decision-making bodies
    52 development
    53 early stages
    54 effective microbicide
    55 environmental changes
    56 evaluation
    57 experience
    58 expertise
    59 female reproductive health
    60 final approval
    61 funding
    62 funding cycle
    63 gap
    64 group
    65 health
    66 improvement
    67 investigators
    68 leadership
    69 leadership group
    70 lessons
    71 management center
    72 manuscript development
    73 microbicide development
    74 microbicides
    75 monitoring
    76 network
    77 network committees
    78 network evaluation
    79 network leadership
    80 obstacles
    81 operational structure
    82 period
    83 pressure
    84 prevention
    85 primary leadership
    86 principal investigator
    87 product development
    88 program
    89 protocol
    90 regulatory authorities
    91 reproductive health
    92 research
    93 research agenda
    94 science
    95 separate application
    96 sites
    97 specific aim
    98 specific areas
    99 stage
    100 structure
    101 support cores
    102 years
    103 years of experience
    104 schema:name Leadership and Operations Center (LOC): Microbicide Trials Network
    105 schema:recipient Na4022bef501d4f70b2f02318b8bcc1f5
    106 sg:person.01036244723.95
    107 grid-institutes:grid.460217.6
    108 schema:sameAs https://app.dimensions.ai/details/grant/grant.2705268
    109 schema:sdDatePublished 2021-12-01T20:14
    110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    111 schema:sdPublisher N86d35101023245e58423bb6bc23891a7
    112 schema:startDate 2006-06-29
    113 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=10174309
    114 sgo:license sg:explorer/license/
    115 sgo:sdDataset grants
    116 rdf:type schema:MonetaryGrant
    117 N18cace79fde049d8aa974f21707a9086 schema:name dimensions_id
    118 schema:value grant.2705268
    119 rdf:type schema:PropertyValue
    120 N86d35101023245e58423bb6bc23891a7 schema:name Springer Nature - SN SciGraph project
    121 rdf:type schema:Organization
    122 N9d6b0ecc05304eb58b7fb98e707f469e schema:currency USD
    123 schema:value 178287648.0
    124 rdf:type schema:MonetaryAmount
    125 Na4022bef501d4f70b2f02318b8bcc1f5 schema:member sg:person.01036244723.95
    126 schema:roleName PI
    127 rdf:type schema:Role
    128 Ncd09402082b440a3946696a4a2899100 schema:name nih_id
    129 schema:value UM1AI068633
    130 rdf:type schema:PropertyValue
    131 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    132 rdf:type schema:DefinedTerm
    133 sg:person.01036244723.95 schema:affiliation grid-institutes:None
    134 schema:familyName HILLIER
    135 schema:givenName SHARON L.
    136 rdf:type schema:Person
    137 grid-institutes:None schema:name MAGEE-WOMEN'S RES INST AND FOUNDATION
    138 rdf:type schema:Organization
    139 grid-institutes:grid.419681.3 schema:Organization
    140 grid-institutes:grid.460217.6 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...